U.S. Markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
27.50+0.56 (+2.08%)
At close: 4:00PM EDT
Sign in to post a message.
  • B
    Bob
    How do they plan to overcome rejection once ALLO-647 is cleared?
  • e
    ed
    B.Riley initiates coverage of Allo at $52
  • B
    Barry
    Picked up more at $28.97
  • e
    ed
    Check out this chart. You can see who has the most assets in play
    https://www.investorvillage.com/groups.asp?mb=19600&mn=23886&pt=msg&mid=21984547
  • J
    James
    Longer term data from the ALLO-501 PhI (ALPHA) trial will be presented alongside initial data from the PhI ALLO-501A (ALPHA2) trial at ASCO. There will be a separate presentation on ALLO-647, to include safety and PK/PD data

    ALLO-501A, is intended for a potentially pivotal PhII trial, which should start in 2H, Previously it has been granted FDA fast track for R/R DLBCL. The company will host a webcast to review the data sets on May 19, at 2:30 pm PT/5:30 pm ET.
  • J
    James
    The AACR poster (other next-gen TurboCARs are being tested) https://www.allogene.com/resources/download/AACR-2021-PD1-iTurboCAR.pdf
  • B
    Barry
    Seems like the only people who are on this board and are going to make money is Ed, James and Frank. Good luck to us all!!!
  • f
    frank
    Buy all you can get your hands
    Bullish
  • e
    ed
    Just be patient and watch the science. So far they have delivered what they said. Biotech investing is not for the faint of heart. We should get a lot more data this year. Based on prior releases it should be a great year
  • B
    Barry
    Bought more shares at $33. I should have waited a little longer before buying. The big drug companies also were hammered down today
  • J
    James
    The FDA has granted RMAT designation* to ALLO-715 in R/R multiple myeloma.

    * It is akin to Breakthrough Therapy status, and provides for the accelerated review of the marketing application as well as more intensive guidance on development.
  • J
    James
    The company has received an IND clearance from the FDA for ALLO-605, the first TurboCAR candidate, for the treatment of patients with R/R multiple myeloma. The trial is expected to begin mid-year.
  • B
    Barry
    I’m a glutton for punishment. Just added more shares at $29.20
  • e
    ed
    This is great news

    Allogene Therapeutics Inc. on Wednesday said the U.S. Food and Drug Administration granted regenerative-medicine-advanced-therapy, or RMAT, designation to ALLO-715 in relapsed/refractory multiple myeloma.

    The South San Francisco, Calif., clinical-stage biotechnology company said the designation is based on its encouraging initial clinical experience in heavily pretreated patients in a Phase 1 study and on the potential of ALLO-715 to address the growing unmet need for patients who have failed other therapies for the blood cancer.

    The FDA's RMAT designation offers eligibility for expedited development and regulatory review of product candidates, including earlier and more frequent consultation with the agency, and the potential for accelerated approval.
  • J
    James
    The first patient has been dosed in a trial evaluating the company's anti-BCMA CAR-T therapy, in combination with nirogacestat in patients with R/R multiple myeloma.
  • f
    frank
    Great news but we need volume
    Bullish
  • e
    ed
    During the past two weeks Allogene has been tracking with the IBB. This is almost to be expected at this point in time with the company. We just need to wait for further data regarding the efficacy of their ongoing studies.

    If you are concerned about how this is trading on a daily basis, this may not be the investment vehicle for you. It is my opinion based on the data they presented, conference calls and presentations at the various bio tech conferences this is going to be a homerun.
  • K
    Kathy
    No earnings, no income, no results, owes Cellectus milestone payments, Cancer trails are small groups with mixed results. Very complicated.
  • B
    Benjo
    Wastage of money. $12-13 at max.
  • B
    Barry
    Loss for the quarter was on the low end at (.26)
    Per share vs a mean of a (.56) loss